Literature DB >> 26195508

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.

Romney M Humphries1, Shangxin Yang2, Peera Hemarajata2, Kevin W Ward2, Janet A Hindler1, Shelley A Miller2, Aric Gregson3.   

Abstract

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26195508      PMCID： PMC4576121          DOI： 10.1128/AAC.01165-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Authors:  Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

Authors:  S Mushtaq; M Warner; G Williams; I Critchley; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-05-17       Impact factor: 5.790

3.  Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme.

Authors:  Sushmita D Lahiri; Robert A Giacobbe; Michele R Johnstone; Richard A Alm
Journal:  J Antimicrob Chemother       Date:  2014-06-30       Impact factor: 5.790

4.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

5.  Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

Authors:  David M Livermore; Shazad Mushtaq; Kevin Barker; Russell Hope; Marina Warner; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2012-03-22       Impact factor: 5.790

Review 6.  Proliferation and significance of clinically relevant β-lactamases.

Authors:  Karen Bush
Journal:  Ann N Y Acad Sci       Date:  2013-01       Impact factor: 5.691

7.  Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Andrea M Hujer; T Nicholas Domitrovic; Kristine M Hujer; Kelly N Hurless; Marion Tuohy; Geraldine Hall; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

8.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

9.  Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.

Authors:  S Pollett; S Miller; J Hindler; D Uslan; M Carvalho; R M Humphries
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

10.  Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Authors:  Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191
View more
  86 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Gain and loss of antibiotic resistant genes in multidrug resistant bacteria: One Health perspective.

Authors:  Misung Kim; Jaeeun Park; Mingyeong Kang; Jihye Yang; Woojun Park
Journal:  J Microbiol       Date:  2021-04-20       Impact factor: 3.422

Review 3.  Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.

Authors:  Ritu Banerjee; Romney Humphries
Journal:  Virulence       Date:  2016-05-11       Impact factor: 5.882

4.  Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Authors:  Krystyna M Kazmierczak; Douglas J Biedenbach; Meredith Hackel; Sharon Rabine; Boudewijn L M de Jonge; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.

Authors:  Kirk Nelson; Peera Hemarajata; Dongxu Sun; Debora Rubio-Aparicio; Ruslan Tsivkovski; Shangxin Yang; Robert Sebra; Andrew Kasarskis; Hoan Nguyen; Blake M Hanson; Shana Leopold; George Weinstock; Olga Lomovskaya; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

6.  Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.

Authors:  Romney M Humphries; Peera Hemarajata
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  Every cloud has a silver lining.

Authors:  Filippo Pieralli; Silvia Baroncelli; Alberto Farese; Antonio Mancini; Fabio Luise; Lucia Sammicheli; Alessandro Bartoloni; Gian Maria Rossolini; Carlo Nozzoli
Journal:  Intern Emerg Med       Date:  2017-05-10       Impact factor: 3.397

Review 8.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

9.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.